HomeCirculationVol. 113, No. 3Issue Highlights Free AccessIn BriefPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessIn BriefPDF/EPUBIssue Highlights Originally published24 Jan 2006https://doi.org/10.1161/circ.113.3.329Circulation. 2006;113:329MORTALITY AND CARDIOVASCULAR RISK ACROSS THE ANKLE-ARM INDEX SPECTRUM: RESULTS FROM THE CARDIOVASCULAR HEALTH STUDY, by O’Hare et al.The ankle arm index (AAI; ratio of ankle and arm systolic blood pressures) has been used as an indicator of subclinical and clinical peripheral vascular disease, and values below 0.9 and above 1.4 have been reported to indicate an adverse vascular prognosis. In this issue of Circulation, O’Hare and colleagues evaluated the mortality and cardiovascular risks associated with a broad range of AAI (categories defined in 0.1 unit increments from 0.6 to 1.4) in a large elderly community-based sample. Compared to the referent group with an AAI between 1.10 and 1.20, values below 1.0 and above 1.4 were associated with higher all-cause and cardiovascular mortality. Specifically, an AAI in the range 0.9 to 1.0 (often regarded as normal) was associated with a 40% higher mortality risk compared to the referent group, whereas a value above 1.40 was associated with a 57% greater mortality hazard. The authors noted effect modification by age, with stronger associations of high and low AAI with mortality risk in people below age 75 years. Overall, these observational data emphasize the nonlinear relations of AAI and mortality risk and raise the possibility that the mortality risk associated with a low AAI may extend to values above the traditional cut point of 0.9 (ie, to the range 0.9 to 1.0). See p 388.IMPACT OF PROSTHESIS-PATIENT MISMATCH ON LONG-TERM SURVIVAL IN PATIENTS WITH SMALL ST JUDE MEDICAL MECHANICAL PROSTHESES IN THE AORTIC POSITION, by Mohty-Echahidi et al.The issue of prosthesis-patient mismatch continues to be an area of active clinical investigation. The article by Mohty-Echahidi et al focuses on long-term survival in a defined population of patients receiving an aortic valve with a small (19 or 21 mm) St Jude prosthesis. Three-hundred eighty-eight patients were studied and the degree of mismatch was measured by postoperative transesophageal echocardiography in each patient. The effective orifice area index is defined as the echo-derived prosthesis effective orifice area divided by the patient’s body surface area. The patients with severely mismatched effective orifice area index <0.6 cm2/m2 comprised 17% of the study patients. These patients were observed to have a significantly worse survival at 5 years (72%) and 8 years (41%) than those patients with moderate mismatch (0.6 cm2/m2 to 0.85 cm2/m2) or no significant mismatch (>0.85 cm2/m2). Severe mismatch was an independent predictor of mortality (hazard ratio=2.18, P=0.007) and congestive heart failure (hazard ratio=3.1, P= 0.009). The ability of a surgeon to predict potential mismatch should be part of current surgical practice. The effective orifice areas for specific valves are available in tables provided by the manufacturers. The surgeon can calculate the effective orifice area index and choose a hemodynamically superior prosthesis or perform an annular enlargement to avoid mismatch, thus improving outcomes in cardiac surgery. See p 420.EFFECT OF INTENSIVE VERSUS STANDARD LIPID-LOWERING TREATMENT WITH ATORVASTATIN ON THE PROGRESSION OF CALCIFIED CORONARY ATHEROSCLEROSIS OVER 12 MONTHS: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL, by Schmermund et al.Emerging clinical trials suggest that low-density lipoprotein (LDL) cholesterol lowering beyond previously defined targets improves clinical outcomes in patients with coronary artery disease and those with multiple cardiovascular risk factors. Quantification of coronary artery calcification by electron-beam computed tomography has been shown to provide prognostic information in patients with known or suspected coronary artery disease. In this issue of Circulation, Schmermund et al evaluate whether intensive LDL lowering using high-dose atorvastatin reduces the presence of coronary artery calcification as assessed by electron-beam computed tomography compared to treatment with low dose atorvastatin. In this randomized controlled trial of 471 patients, the mean LDL after 12 months of treatment was 87±33 mg/dL in the high-dose group and was 109±28 mg/dL in the low-dose group. However, the progression in calcium score did not differ between groups. This unexpected funding may have implications for the clinical utility of coronary calcium score as a surrogate marker for cardiovascular risk. See p 427.Visit http://www.circ.ahajournals.org:Images in Cardiovascular MedicineNot So Mural Thrombus. See p e38.Cardiomyopathy Resulting From Primary Hyperoxaluria Type II. See p e39.Role of Inflammation in Atherosclerosis: Immunohistochemical and Electron Microscopic Images of a Coronary Endarterectomy Specimen. See p e41. Download figureDownload PowerPointCorrespondenceSee p e44. Previous Back to top Next FiguresReferencesRelatedDetails January 24, 2006Vol 113, Issue 3 Advertisement Article InformationMetrics https://doi.org/10.1161/circ.113.3.329 Originally publishedJanuary 24, 2006 PDF download Advertisement
Read full abstract